NSRX Nasus Pharma Ltd.: רווח נקי למניה ב-12 החודשים האחרונים

The market price visualization of EPS (TTM) for Nasus Pharma Ltd (NSRX) demonstrates a figure of 0.00. Business stability relies on regulatory approvals and the success of tests for treatments against viral infections and overdoses. B2B contracts and the implementation of unique nasal drug delivery methods drive positive momentum. Despite its narrow specialization in emergency airway protection, Nasus Pharma Ltd (NSRX) successfully monetizes its developments through retail pharmacies.
פילוחי מדדים פיננסיים ומדדי שוק עבור Nasus Pharma Ltd (NSRX)

This indicator measures the net profit per share dynamics over the last twelve months, allowing investors to filter out market noise and assess the actual efficiency of capital generation. By analyzing the current EPS YoY TTM growth rate, one can compare market volatility with the results of the Nasus Pharma (NSRX) pharmaceutical team's efforts to monetize intellectual property and implement its technological platforms.